Latest
Bing-Neel Syndrome: Managing Patients With Waldenström Macroglobulinemia Characterized by CNS Involvement
Real-World Outcomes With Ibrutinib in Waldenström Macroglobulinemia
Clinical Relevance of Key Genetic Mutations in Primary and Secondary Myelofibrosis
Real-World Insight on Patients With Multiple Myeloma: Results Drawn From a Large Health Plan
Idelalisib-Rituximab Combo Found Active in R/R CLL Regardless of Complex Karyotype
Consensus Opinion Addresses Concerns About Clinical Application of CAR-T
Study Compares Quality of Life for Patients With Chronic Myeloid Leukemia Treated With Dasatinib vs Imatinib
Mechanism Unearthed for Carfilzomib-Induced Reticulocytosis in Myeloma
Investigation of the Causes of Extreme Thrombocytosis
Prevalence of Hypertension Higher With Myeloproliferative Neoplasms Than in General Population
No Benefit With Upfront Rituximab and Autologous HSCT Consolidation for Aggressive Non-Hodgkin Lymphomas
Health Care Costs With Bypassing Therapy vs Factor VIII Replacement for Hemophilia A
Featured Content
Current and Prospective Treatment Strategies for Myeloproliferative Neoplasms
Several novel treatment agents for myeloproliferative neoplasms are currently being studied in phase 1 or phase 2 trials.
Implant-Associated Cancers: A Look Beyond BIA-ALCL
Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants.
Making Treatment Decisions About Discontinuing TKIs in Chronic Myeloid Leukemia
Researchers are assessing the value and safety of discontinuing TKI therapy in patients with chronic phase CML who have achieved deep molecular response.
Treatment Delays With CAR-T Therapy: A High Price to Pay
A treatment delay of 6 months was found to result in up to a 67.3% loss in social value for patients receiving chimeric antigen receptor T-cell therapy.
Maintenance Therapy in Acute Myeloid Leukemia: An Overview
In a review article, researchers discussed maintenance treatment strategies using chemotherapy, immunotherapy, targeted small molecules, and more.
